The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
Dengue, a mosquito-borne viral disease, is emerging as a growing public health threat across Africa
Broadening access for children & patients with inhibitor-complicated hemophilia
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The campaign places renewed focus on a disease that remains incurable despite major scientific advances
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
MSD joins as anchor customer as Aurobindo strengthens its position in the fast-growing global biologics manufacturing market
Targeting deadly drug-resistant acinetobacter infections
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
